People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Origen Therapeutics Inc /Ca | — | Biotechnology | Seed | $3.7M | $166.2M | 2010 |
| Cell Genesys Inc | — | Biotechnology | Pre-Seed | $310K | $17.1M | 2009 |
David W. Carter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David W. Carter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas E. Shenk | 1 | 2 |
| Dennis L. Winger | 1 | 2 |
| Marc L. Belsky | 1 | 2 |
| Robert W. Kay | 1 | 1 |
| Spencer W. Wang | 1 | 1 |
| Timothy W. Harris | 1 | 1 |
| Lynda W. Wijcik | 1 | 1 |
| JAMES M GOWER | 1 | 1 |
| STEPHEN A SHERWIN | 1 | 1 |
| ROBERT H. TIDWELL | 1 | 1 |
| NANCY M CROWELL | 1 | 1 |
| INDER M VERMA | 1 | 1 |
| SHARON E TETLOW | 1 | 1 |
| JOHN T POTTS, JR. | 1 | 1 |
| EUGENE L STEP | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.